Lumbrokinase versus placebo for recent ischemic stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether lumbrokinase, a medicine that may break up blood clots, can help people who recently had an ischemic stroke (a stroke caused by a blocked blood vessel in the brain). You must start treatment within 24 hours of your stroke and before receiving any clot-busting or clot-removing procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You had an acute ischemic stroke confirmed by CT or MRI, and your stroke symptoms are moderate to severe (but not extremely severe).
- You were independent before the stroke (able to do daily activities without help).
- You can start the study drug within 24 hours of when you were last known to be well.
- You have not had and are not planning to have clot-busting drugs (like tPA) or clot-removal procedures for this stroke.
- You do not have conditions that increase bleeding risk (e.g., recent major surgery, bleeding disorders, low platelets) or other stroke causes like heart problems or artery tears.
- You have normal liver and kidney function, no history of bleeding in the brain, no active cancer, and are not pregnant or breastfeeding.
- You are able to give informed consent and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single dose of a new clot-dissolving medicine for people who had a stroke 4.5 to 24 hours ago. It may help if you cannot have standard treatments like a clot-removal procedure or other clot-busting drugs.
This trial tests a clot-dissolving medication (pro-urokinase) for people with recent strokes in the back of the brain. You would be treated 4.5 to 9 hours after symptoms start, which is beyond the typical treatment window, using special MRI patterns to identify patients most likely to benefit.
This trial tests whether the clot-busting drug urokinase can help people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to dissolve the clot and improve recovery, as long as treatment starts within 6 hours of the first symptoms.
This trial tests an investigational drug called LT3001 for people who have had an acute ischemic stroke (a type of stroke caused by a blocked blood vessel in the brain). The drug is given within 24 hours of the stroke to help reduce the damage and improve recovery. Participating could offer access to a new treatment option that may help improve outcomes.
This trial tests whether giving a clot-dissolving medicine (alteplase or tenecteplase) is safe and effective for people who have had a stroke and are taking a blood thinner (DOAC) like apixaban or rivaroxaban. It aims to see if this treatment can still be given within a few hours of the stroke.
This trial tests a medicine called tenecteplase (a clot-buster) for people who have a moderate or severe stroke caused by a clot and can be treated 4.5 to 6 hours after symptoms start. It aims to see if this medicine can help improve recovery.
Hear when a new Ischemic Stroke, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.